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uantitative Hyperemic Reactivity in
pposed Limbs During Myocardial Perfusion Imaging
New Marker of Coronary Artery Disease
ocelyn Dupuis, MD, PHD,* André Arsenault, MD,† Bernard Meloche,† François Harel, MD,†
ezar Staniloae, MD,‡ Jean Grégoire, MD†
ontreal, Quebec, Canada; and New York, New York
OBJECTIVES We sought to evaluate the feasibility and validity of a new method to quantify the hyperemic
response of the forearms that can be incorporated into a rest myocardial perfusion protocol.
BACKGROUND Evaluation of the hyperemic response could provide useful clinical information in the
detection and risk stratification of atherosclerotic vascular disease.
METHODS Patients with proven coronary artery disease (CAD) (n  46) were compared with low-risk
subjects without such evidence (n  47). A regular dose of Myoview was injected after 5 min
of right arm ischemia. Three dimensionless parametric ratios (right/left) were derived from
the analysis of activity-time curves of the hyperemic right forearm and that of the contralateral
left forearm.
RESULTS The maximal ingress upslope ratio was 40% lower in the CAD group (3.0  0.2 vs. 4.2 
0.3, p 0.0005), and the integral to peak ratio was also lower (23 4 vs. 52 11, p 0.01),
whereas the peak activity ratio was nonsignificantly lower (3.0 0.3 vs. 3.8 0.3, p 0.07).
Using a value of 3.55 for the maximal upslope ratio, this approach could predict the presence
of CAD with a sensitivity of 0.70 and a specificity of 0.60.
CONCLUSIONS This simple and noninvasive method is feasible and can discriminate between patients with
known CAD and those at low risk of atherosclerosis. Refinements of this approach and its
inclusion in larger clinical trials are needed to determine whether it could provide additional
value to myocardial scintigraphic imaging. (J Am Coll Cardiol 2004;44:1473–7) © 2004 by






















the reactive hyperemic response corresponds to an increase
n blood flow after the relief of a period of ischemia. Various
linical approaches have been used in an effort to quantify
his response and its physiologic determinants in the upper
r lower limbs (1–3), the skin (4), the finger tips, and the
See page 1478
ailbeds (5). A method that is rapidly gaining in popularity
s the ultrasound measurement of flow-mediated dilation
FMD) of the brachial artery during reactive hyperemia (6).
reduced percent increase in brachial artery diameter,
hich is modulated by the integrity of the vascular endo-
helium, relates to risk factors for coronary artery disease
CAD), as well as to the presence of CAD itself, and is
redictive of future cardiovascular events (6).
These methods of evaluation of the hyperemic response,
owever, require specialized equipment and/or technical
From the *Departments of Medicine and †Nuclear Medicine, Montreal Heart
nstitute, Montreal, Quebec, Canada; and the ‡Comprehensive Cardiovascular
enter, Saint Vincent’s Medical Center Manhattan, New York, New York. Dr.
upuis is a senior scholar from the Fonds de la Recherche en Santé du Québec and
his work was supported by the Fonds de Recherche de l’Institut de Cardiologie de
ontréal.
Manuscript received November 7, 2003; revised manuscript received February 19,n004, accepted February 24, 2004.kills not currently readily available in most centers. We
ave developed a novel noninvasive method to evaluate the
eactive hyperemic response that can be performed during
he same session of a rest myocardial perfusion study. The
pproach is based on the intravenous injection of the
yocardial perfusion agent Myoview and the simultaneous
oninvasive external detection of the tracer ingress and
ransit into both forearms: the one submitted to reactive
yperemia and the contralateral non-hyperemic one. This
oninvasive method would allow for repeated measure-
ents, minimize human intervention, and provide numer-
cal data allowing precise quantification, and, most impor-
antly, it has the potential of easy incorporation into any
enter with nuclear medicine facilities.
The present study was therefore designed to validate the
easibility and explore the potential clinical utility of the
etermination of the scintigraphic hyperemic reactivity
SHR) by comparing a group of patients with known CAD
o a low-risk group with no known CAD.
ETHODS
he study protocol had been approved by the Research and
thics Committee of the Montreal Heart Institute, and all
ubjects gave informed consent. Subjects were included if
hey were adults over 40 years old. Postmenopausal women
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Hyperemic Reactivity October 6, 2004:1473–7ubjects were excluded if they had known heart failure with
n ejection fraction 40%, signs of peripheral artery disease
n the upper limbs as evidenced by a 20 mm Hg blood
ressure difference between arms, and a recent (10 days)
cute coronary syndrome. Premenopausal women were also
xcluded.
The CAD group (n  46) was recruited among patients
eferred for myocardial scintigraphy at the Montreal Heart
nstitute. They all had previous evidence of CAD, as
emonstrated by at least one of the following: revascular-
zation procedure by surgery or angioplasty, acute coronary
yndrome, and/or documented significant CAD by angiog-
aphy or myocardial scintigraphy. The control group (n 
7) was recruited from health-conscious members of a
ealth fitness facility affiliated with the Montreal Heart
nstitute. These subjects all had a negative symptom-limited
xercise stress test. With the possible exception of older age,
hey were not included if they had more than one other
nown traditional risk factor for CAD. In this group, only
rest myocardial study was performed.
The SHR study was thus performed before the rest
yocardial imaging study, taking advantage of the same
njection of the myocardial perfusion agent technetium-
9m–tetrofosmin (Myoview). A standard single-photon
mission computed tomographic (SPECT) myocardial per-
usion imaging at rest was carried out about 45 min later in
ll cases.
cintigraphic forearm blood flow measurement proce-
ures. The procedure used to determine SHR has been
ranted protection by the U.S. patent office (patent no.
S-6445945). In a sitting position, both arms are extended
ver the top of a large field-of-view gamma camera facing
pward, hands prone. The right upper arm was instru-
ented with a blood pressure cuff, and occlusion of arterial
ow was achieved by rapidly inflating the cuff to 50 mm Hg
igher than the systolic pressure for 5 min. After sudden
elease, a 30-s lag period was observed before injecting
yoview (0.42 mCi/kg) in a small catheter positioned in
he bend of the left arm. Allowing for an estimated 30 s of
irculation time delay, the timing was targeted to reach the
etector at the moment corresponding to the maximum
MD detected using ultrasound probes (60 s). Dynamic
mages acquisitions were realized using 128  128 matrices
t a sampling rate one frame per second for 10 min.
rchiving and data parameters analysis. Regions of in-
Abbreviations and Acronyms
CAD  coronary artery disease
FMD  flow-mediated dilation
HDL  high-density lipoprotein
ROC  receiver operating characteristics
SHR  scintigraphic hyperemic reactivity
SPECT  single-photon emission computed
tomographicerest over the two forearms, limited by the bend of the armnd excluding the wrist, were determined. The dynamic
tudies, together with the activity-time curves generated,
ere transferred to a standard personal computer environ-
ent. The raw activity-time curves were filtered, displayed,
nd analyzed using a proprietary software. Parameters in-
icative of the SHR were computed as the ratio of the
yperemic right arm over the control left arm (see Results
ection). The variability of this method was determined in
5 subjects on two consecutive days. The values for the ratio
f maximal upslope were 5.3  0.8 on day 1 and 4.9  0.5
n day 2 (mean SEM), with an absolute difference of 1.33
0.21 and a correlation coefficient of 0.89.
tatistical analysis. Comparisons of parameters between
he CAD and control groups were evaluated by the two-
ailed t test for continuous variables and the chi-square test
or non-continuous variables. All data are presented as the
ean value  SEM. All analyses, including receiver oper-
ting characteristics (ROC) curves, were performed with the
CSS statistical package.
ESULTS
emographic, physiologic, and biochemical parameters are
hown in Table 1. Patients in the CAD group were about
ix years older. Systolic blood pressure in both arms was
igher in the CAD group. Ejection fraction and other left
entricular parameters derived from myocardial SPECT
maging were similar in both groups. High-density lipopro-
ein (HDL) cholesterol was lower in the CAD group,
hereas triglycerides were higher. The ratio of total/HDL
holesterol and levels of blood glucose and creatinine were
ll higher in the CAD subjects. Patients in the control
roup did not take any cardiovascular medications.
Typical examples of Myoview activity-time curves and
cintigraphic imaging during SHR in the hyperemic right
rm and non-hyperemic left arm of a control subject are
hown in Figure 1A. Tracer activity in the hyperemic right
rm appears first, displays a steeper slope, and reaches a
igher peak than that in the non-hyperemic left arm. By
omparison, an example taken from a patient with CAD
Fig. 1B) displays a less pronounced difference in the slopes
f both arms, as well as peak tracer activity attained.
Based on the appearance of these curves and in order to
uantify the hyperemic response of the right arm as com-
ared with the control left arm, three dimensionless para-
etric ratios were derived: the ratios of the peak activities,
f the maximal rate of rise of activities (upslope), and of the
ntegral of the activity-time curves up to the peak activity of
he hyperemic right arm. Consequently, these ratios should
epart from unity in relation to the importance of the
yperemic response. In the particular example of a control
ubject (Fig. 1A), the parametric ratios were 6.0 for the peak
ctivity, 7.7 for maximal slopes, and 344 for the integral, as
ompared with 1.3, 1.5, and 11 for the same parametric
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October 6, 2004:1473–7 Hyperemic ReactivityAD patients (3.0  0.3) compared with controls (3.8 
.3), although this did not reach statistical significance (p 
.07). The ratio of maximal upslopes (Fig. 2A) was 40%
ower in the CAD patients (3.0  0.2) compared with
ontrols (4.2  0.3, p  0.0005). The ratio of the integrals
p to the peak activity of the right arm (Fig. 2C) was about
0% lower in the CAD group (23  4) compared with
ontrols (52  11, p  0.01). Using a threshold value of
.55, the ratio of the maximal slopes alone predicted the
resence of known CAD with a sensitivity of 0.70 and a
pecificity of 0.60, with an area under the ROC curve of
.70 (Fig. 3).
ISCUSSION
e evaluated the feasibility and potential clinical utility of
esting the integrity of vascular reactivity using a novel
oninvasive approach based on the reactive hyperemic
Table 1. Sociodemographics and Clinical Desc
CAD Gro
Sociodemographics
Age (yrs) 63.7 1
Gender (M/F) 43/3
Physiologic
Blood pressure (mm Hg)
Systolic
Right 134  3
Left 137  3
Diastolic
Right 70  1
Left 71  1
End-diastolic volume (ml) 124.6 5
End-systolic volume (ml) 60.0 4
Stroke volume (ml) 64.4 2
Ejection fraction (%) 54.2 1
Weight (kg) 82.2 2
Height (cm) 168  1
Body mass index (kg/m2) 28.8  0
Biochemical
Cholesterol total (mmol/l) 4.67 0
HDL (mmol/l) 1.08 0
LDL (mmol/l) 2.70 0
Triglycerides (mmol/l) 1.89 0
Cholesterol/HDL 4.36 0
Glucose (mmol/l) 6.62 0
Creatinine (mmol/l) 99.5 3
C-reactive protein (mg/dl) 2.6  0
Pharmacologic
Beta-blockers 25 (61%
Calcium blockers 14 (34%
ACE inhibitors 17 (41%
ASA 35 (85%
Nitrates 9 (22%




ACE  angiotensin-converting enzyme; ASA  acetylsalic
artery disease; HDL  high-density lipoprotein; LDL  loesponse. The primary objective was to test the hypothesis chat this new method that we called SHR would result in
ower responses in a population with known CAD at high
isk of cardiovascular events, as compared with a low-risk
opulation without known CAD. Quantitative analysis
evealed that the ratio of the maximal upslope between the
yperemic and the control arm best predicted whether
ubjects belonged to the CAD group (p  0.0005). The
ncrease in forearm blood flow during reactive hyperemia is
complex response modulated by several mechanisms,
ncluding the release of endothelium-derived vasoactive
actors and adenosine (3,7–10), the activation of mechanical
actors and neurogenic reflexes (11), and the modification of
mooth muscle ion channels (1,12).
Different methods have been used and are being devel-
ped to noninvasively evaluate reactive hyperemia and its
eterminants in man. These include plethysmography, laser
oppler flowmetry, near infrared spectrometry, and trans-
n of Sample
Control Group p Value
56.5  1.5 0.001
41/6 0.3
121  2.0 0.001
122  1.9 0.0007
71  1.5 0.5
70  1.7 0.8
113.3  3.9 0.1
51.0  2.5 0.09
62.3  1.7 0.4
56.1  1.0 0.5
79.6  1.8 0.4
167  1 0.7
28.3  0.5 0.6
5.00  0.14 0.1
1.43  0.06 0.000001
3.05  0.12 0.08
1.28  0.09 0.002
3.76  0.18 0.01
5.23  0.08 0.0005
91.4  1.7 0.03










d; ARB  angiotensin receptor blocker; CAD  coronary
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Hyperemic Reactivity October 6, 2004:1473–7etric capillaroscopy of the nailbed and measurement of
ulsatile variations in finger tip volume (5).
A method that is most rapidly gaining in popularity is the
igh-resolution ultrasound measurement of FMD of the
rachial artery during the reactive hyperemic response (6).
he maximal increase in the brachial artery diameter after
he release of 5 min of forearm ischemia occurs after a mean
f 1 min. Some recent trials have reported the potential
alue of the determination of FMD by brachial ultrasound
s a predictor of future cardiovascular events. Brachial
ltrasound, however, suffers from technical and interpreta-
ive limitations, which have thus far limited its use to
esearch (6).
In the present experiments, in light of the potentially
igure 1. Typical example of scintigraphic hyperemic reactivity experimen
B). In the control subject, there is more intense tracer activity in the hype
igher in the control subject with a ratio of maximal upslopes between the h
f 6.0, and a ratio of integrals between t0 and tmax of 344. The same valu
igure 2. Mean values for the parametric ratios derived from the analysis
f the activity-time curves of the hyperemic right arm divided by that of the
ontralateral left arm. CAD  coronary artery disease. smportant clinical/practical value of an abnormal hyperemic
esponse to predict future cardiovascular events, we explored
nother different approach to the evaluation of reactive
yperemia by taking advantage of the customary injection of
yoview for the resting phase of scintigraphic myocardial
erfusion studies. We evaluated the SHR in the right
yperemic arm and used the non-hyperemic left arm as a
ontrol. We found marked significant differences of the
rder of 40% to 50% in the ratio of maximal upslopes and of
m a control subject (A) and a patient with coronary artery disease (CAD)
right arm. The parametric ratios derived from the activity-time curves are
mic right arm over the control left arm of 7.7, a ratio of the peak activities
the CAD patient were lower at 1.3, 1.4, and 11, respectively.
igure 3. The receiver-operating characteristic curve of the predictive value
he ratio of maximal upslopes during scintigraphic hyperemic reactivity for
he detection of patients with proven coronary artery disease. Using a
hreshold value of 3.55, this parameter has a sensitivity of 0.70 and ats fro
remic
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October 6, 2004:1473–7 Hyperemic Reactivityhe integrals of the time-activity curves during SHR. The
atio of the maximal upslopes between the arms was the
ost predictive of the presence of known CAD. Although
he higher systolic blood pressure in the CAD group, with
ossibly higher systemic vascular resistance, may have af-
ected our findings, the very small difference in blood
ressure and the lack of correlation with the ratio of
aximal upslopes (r  0.02) suggest that this would be
inimal, however.
The hyperemic response is determined by increased flow
hrough modification of both small resistance vessels and
arger conductance vessels. We measured the response at a
ime when maximal dilation of conductance vessels is
nown to occur, but after a peak increase in flow, which
ccurs immediately after cuff release. Although more studies
re needed to understand the determinants of SHR, the
espective role of conductance versus resistance vessels, and
he optimal timing and analytical approach to the generated
ata, our results suggest a potential clinical utility of this
ethod, which could be readily incorporated into any
uclear medicine department.
In order to perform the determination of SHR, we
sed the myocardial perfusion agent technetium-99m–
etrofosmin (Myoview). Use of a myocardial perfusion agent
lso confers potential advantages to SHR determination, as
he test can be performed during the same session as the
yocardial resting images, using the same injection.
hether additional diagnostic and prognostic information
ould be gained by simultaneous investigation of myocardial
erfusion and endothelial function remains to be deter-
ined, but could easily be tested with this approach.
onclusions. The SHR of the forearm can be evaluated at
he same time as resting myocardial perfusion scintigraphy.
his simple and noninvasive method can discriminate
etween patients with known CAD and those at low risk of
therosclerosis. Refinements of this approach and its inclu-
ion in larger clinical trials are needed to determine whether
HR could provide additional value to myocardial scinti-
raphic imaging.eprint requests and correspondence: Dr. Jocelyn Dupuis, Research
enter, Montreal Heart Institute, 5000 Belanger East, Montreal,
uebec, Canada, H1T 1C8. E-mail: jocelyn.dupuis@bellnet.ca.
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